1. Germany Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
MorphoSys AG

MorphoSys AG

MPSYF
MorphoSys AGUS flagOther OTC
73.27
USD
+1.51
- -
2.76BMarket Cap
MorphoSys AG
MPSYF
(Other OTC)

Recent

price

73.27

P/E

ratio

- -

div

yld

- -

ROIC.AI

2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
TTM
FRC
3.22
3.6
3.84
3.59
2.26
3.18
2.47
4.08
1.88
2.31
2.44
2.27
9.88
5.38
8.15
6.94
6.98
Revenue per Share
0.59
0.4
0.41
0.36
0.08
0.54
-0.12
0.57
-2.28
-2.41
-1.79
-3.26
2.95
-15.4
-4.42
-5.53
-5.55
Basic EPS, GAAP
1.11
-0.21
-0.53
1.03
-0.02
3.41
-1.34
-1.24
-1.87
-1.78
-1.12
-2.68
-0.42
-15.2
-11.18
-8.71
-5.79
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
6.2
0.49
0.9
1.26
1.35
1.92
1.71
2.28
0.06
-2.35
-3.86
-7.08
-3.77
-19.1
-23.11
-28.43
-28.55
Book Value per Share
5.2
5.78
5.15
5.73
7.26
12.94
11.69
10.88
13.14
10.05
14.07
11.07
16.59
-27.81
-31.78
-33.15
-33.29
Tangible Book Value per Share
22
22
23
23
23
25
26
26
26
29
31
32
33
33
34
34
34
Basic Weighted Avg Shares
72
81
87
82
52
78
64
106
50
67
76
72
328
180
278
238
238
Sales/Revenue/Turnover
22.92
14.08
11.32
14.3
4.7
13.01
-9.07
12.1
-120.12
-100.4
-78.57
-150.51
6.12
-154.57
-79.32
-105.28
-105.22
Operating Margin (%)
5
5
6
7
6
5
4
3
4
4
4
6
8
10
11
11
6
Depreciation Expense
13
9
9
8
2
13
-3
15
-60
-70
-56
-103
98
-514
-151
-190
-190
Net Income, GAAP
26.87
31.22
30.18
26.72
22.47
30.99
- -
27.76
- -
- -
- -
- -
- -
- -
962.15
- -
- -
Effective Tax Rate (%)
18.36
11.07
10.57
10.01
3.74
17.09
-4.71
14.03
-121.39
-104.54
-73.48
-143.56
29.87
-286.43
-54.29
-79.63
-79.6
Profit Margin (%)
123
131
111
131
168
371
290
273
270
293
343
242
1,006
848
811
550
550
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
40
315
322
688
622
622
LT Debt
162
174
186
197
202
352
349
363
415
359
488
395
621
245
157
49
49
Total Equity
7.81
4.65
3.78
4.39
0.93
2.5
- -
2.6
- -
- -
- -
- -
- -
- -
266.76
- -
- -
Return on Invested Capital (%)
20.84
12.05
58.66
33.38
6.5
33.97
- -
28.62
- -
- -
- -
- -
- -
- -
572.88
- -
- -
Return on Capital (%)
- -
12.05
58.81
33.43
6.5
34.09
-6.58
28.72
-198.03
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'23
Sep'23
Dec'23
ST Debt
5
- -
14
LT Borrowings
240
- -
613
LT Finance Leases
36
- -
9
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
34
- -
38
Market Capitalization
950
919
1,269

Working Capital

FRC

•

in mil. unless spec.
Jun'23
Sep'23
Dec'23
Total Current Assets
863
- -
814
Cash, Cash Equivalents & STI
672
- -
683
Accounts Receivable, Net
71
- -
32
Inventories
72
- -
62
Total Current Liabilities
242
- -
264
Payables & Accruals
121
- -
110
ST Debt
5
- -
14
Deferred Revenue
- -
- -
19

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-8.68%
-25.38%
-68.84%
Free Cash Flow
339.64%
703.79%
-21.79%
Net Income, GAAP
-200.86%
-156.45%
25.6%
Sales/Revenue/Turnover
38.96%
69.19%
-14.37%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
47
38
41
53
180
2022
41
59
96
82
278
2023
62
53
64
59
238

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
-1.27
0.64
-3.3
-11.16
-15.4
2022
-3.59
-6.88
-3.6
- -
-4.42
2023
-1.3
-2.16
-3.5
- -
-5.53

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Similar Companies
China Resources Boya Bio-pharmaceutical Group Co., Ltd. (300294.SZ)
Transgene Biotek Limited (TRABI.BO)
Race Oncology Limited (RAONF)
Ascendis Pharma A/S (ASND)
Aurinia Pharmaceuticals Inc. (AUPH)
Avacta Group Plc (AVCT.L)
Business
MorphoSys AG is a Germany-based commercial-stage biopharmaceutical company that discovers, develops and commercializes innovative therapies focused on oncology, particularly blood cancers such as leukemia; its main products include Minjuvi (tafasitamab), a CD19-directed cytolytic monoclonal antibody approved for relapsed or refractory diffuse large B-cell lymphoma in combination with lenalidomide; pelabresib, a BET inhibitor in late-stage development for myelofibrosis; and ianalumab, an anti-BAFF monoclonal antibody under investigation for autoimmune diseases including Sjögren's syndrome; the company employs proprietary antibody discovery platforms including HuCAL and Ylanthia for generating fully human therapeutic antibodies, protein engineering technologies and peptide scaffolds; founded in 1992 and headquartered in Planegg near Munich, MorphoSys operates globally with a subsidiary in Boston, Massachusetts, targeting patients with hematologic malignancies and solid tumors through clinical-stage and partnered programs with pharmaceutical collaborators; in 2024, Novartis completed its EUR 2.7 billion acquisition of MorphoSys, integrating its oncology pipeline including pelabresib and ianalumab into Novartis' portfolio, followed by voluntary delistings from Nasdaq and the Frankfurt Stock Exchange, a merger squeeze-out of minority shareholders at EUR 68 per share, and management board appointments of Arkadius Pichota and Lukas Gilgen.